BioSpace News Archive

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, reported preliminary financial and operational highlights for the fourth quarter and fiscal year ended December 31, 2022.

Annexon, Inc. reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, provided its 2023 outlook.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that Chief Executive Officer, Barry Greene, will discuss the Company’s progress in developing a leading brain health pipeline at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Exact Sciences Corp. announced that the company expects to report revenue between $550.7 million and $552.7 million for the fourth quarter ended Dec. 31, 2022.

RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2022.

Hologic, Inc. announced preliminary revenue results for its first fiscal quarter ended December 31, 2022.

IMV Inc., a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S.

Agios Pharmaceuticals, Inc. announced its anticipated 2023 milestones and significant value-driving catalysts through 2026 that support the company’s mission to transform patient outcomes in rare diseases.

Jacobio Pharma announced it has completed the first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S.